Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
William Blair Maintains Outperform On Pandora Media Following 2Q14 Results http://www.smarteranalyst.com/2014/07/25/william-blair-maintains-outperform-on-pandora-media-following-2q14-results/
William Blair Maintains Market Perfom On Pacific Biosciences Following 2Q14 Results http://www.smarteranalyst.com/2014/07/25/william-blair-maintains-market-perfom-on-pacific-biosciences-following-2q14-results/
$AMZN Amazon: We Recommend Long-Term Investors Take Advantage Of Stock Weakness, Says William Blair http://www.smarteranalyst.com/2014/07/25/amazon-we-recommend-long-term-investors-take-advantage-of-stock-weakness-says-william-blair/
$AMZN Amazon: We Recommend Long-Term Investors Take Advantage Of Stock Weakness, Says William Blair http://www.smarteranalyst.com/2014/07/25/amazon-we-recommend-long-term-investors-take-advantage-of-stock-weakness-says-william-blair/
Amazon: We Recommend Long-Term Investors Take Advantage Of Stock Weakness, Says William Blair http://www.smarteranalyst.com/2014/07/25/amazon-we-recommend-long-term-investors-take-advantage-of-stock-weakness-says-william-blair/
Wedbush Reiterates Outperform On Pharmacyclics As CHMP Recommends EU Approval Of Imbruvica http://www.smarteranalyst.com/2014/07/25/wedbush-reiterates-outperform-on-pharmacyclics-as-chmp-recommends-eu-approval-of-imbruvica/
$PCYC Wedbush Reiterates Outperform On Pharmacyclics As CHMP Recommends EU Approval Of Imbruvica http://bit.ly/WHk1hV
$DRWI Canaccord Maintains Hold On DragonWave Following Public Offering http://www.smarteranalyst.com/2014/07/25/canaccord-maintains-hold-on-dragonwave-following-public-offering/
$DRWI $DRWI Canaccord Maintains Hold On DragonWave Following Public Offering http://www.smarteranalyst.com/2014/07/25/canaccord-maintains-hold-on-dragonwave-following-public-offering/
Canaccord Maintains Hold On DragonWave Following Public Offering http://www.smarteranalyst.com/2014/07/25/canaccord-maintains-hold-on-dragonwave-following-public-offering/
$TPX Wedbush Reiterates Buy On Tempur Sealy Following 2Q14 Results http://www.smarteranalyst.com/2014/07/25/wedbush-reiterates-buy-on-tempur-sealy-following-2q14-results/
$ALGN We Find Align’s Current Valuation As An Attractive Entry Point, Says Roth Capital http://www.smarteranalyst.com/2014/07/25/we-find-aligns-current-valuation-as-an-attractive-entry-point-says-roth-capital/
$ALGN We Find Align’s Current Valuation As An Attractive Entry Point, Says Roth Capital http://www.smarteranalyst.com/2014/07/25/we-find-aligns-current-valuation-as-an-attractive-entry-point-says-roth-capital/
$AGEN H.C. Wainwright Reiterates Buy On Agenus Following 2Q14 Results http://www.smarteranalyst.com/2014/07/25/h-c-wainwright-reiterates-buy-on-agenus-following-2q14-results/
$PSTI Maxim Maintains Buy On Pluristem Following R&D Events; Sees Significant Upside http://www.smarteranalyst.com/2014/07/24/maxim-maintains-buy-on-pluristem-following-r-sees-significant-upside/
$UA Under Armour Should Be A Core Long-Term Holding, Says Sterne Agee; Raises PT To $75 http://www.smarteranalyst.com/2014/07/24/under-armour-should-be-a-core-long-term-holding-says-sterne-agee-raises-pt-to-75/
$UA Under Armour Should Be A Core Long-Term Holding, Says Sterne Agee; Raises PT To $75 http://www.smarteranalyst.com/2014/07/24/under-armour-should-be-a-core-long-term-holding-says-sterne-agee-raises-pt-to-75/
$CELG Cowen Raises Celgene Price Target To $96 Following Q214 Resutls http://bit.ly/1z8AARi
$VRTX Current Trading Levels Reflect Appropriate Value For VRTX Shares, Says H.C. Wainwright http://www.smarteranalyst.com/2014/07/24/current-trading-levels-reflect-appropriate-value-for-vrtx-shares-says-h-c-wainwright/
$PSTI Maxim Maintains Buy On Pluristem Following R&D Events; Sees Significant Upside http://www.smarteranalyst.com/2014/07/24/maxim-maintains-buy-on-pluristem-following-r-sees-significant-upside/
$SRPT Janney Capital Reiterates Sell On Sarepta Following CSO Termination; $13 PT http://www.smarteranalyst.com/2014/07/24/janney-capital-reiterates-sell-on-sarepta-following-cso-termination-13-pt/
$SRPT Janney Capital Reiterates Sell On Sarepta Following CSO Termination; $13 PT http://www.smarteranalyst.com/2014/07/24/janney-capital-reiterates-sell-on-sarepta-following-cso-termination-13-pt/
$FB Facebook Remains Our Top Pick Following Better Than Expected Quarter Earnings, Says Topeka http://www.smarteranalyst.com/2014/07/24/facebook-remains-our-top-pick-following-better-than-expected-quarter-earnings-says-topeka/
$FB Facebook Remains Our Top Pick Following Better Than Expected Quarter Earnings, Says Topeka http://www.smarteranalyst.com/2014/07/24/facebook-remains-our-top-pick-following-better-than-expected-quarter-earnings-says-topeka/
$FB Facebook Remains Our Top Pick Following Better Than Expected Quarter Earnings, Says Topeka http://www.smarteranalyst.com/2014/07/24/facebook-remains-our-top-pick-following-better-than-expected-quarter-earnings-says-topeka/
$FB Facebook Remains Our Top Pick Following Better Than Expected Quarter Earnings, Says Topeka http://www.smarteranalyst.com/2014/07/24/facebook-remains-our-top-pick-following-better-than-expected-quarter-earnings-says-topeka/
$FB Facebook Remains Our Top Pick Following Better Than Expected Quarter Earnings, Says Topeka http://www.smarteranalyst.com/2014/07/24/facebook-remains-our-top-pick-following-better-than-expected-quarter-earnings-says-topeka/
Roth Capital Maintains Buy On UR-Energy, Sees %32 Upside http://www.smarteranalyst.com/2014/07/23/roth-capital-maintains-buy-on-ur-energy-sees-2-upside/
$SRPT Sarepta: We Believe That Eteplirsen Accelerated Approval Is Likely, Says Roth Capital http://www.smarteranalyst.com/2014/07/23/sarepta-we-believe-that-eteplirsen-accelerated-approval-is-likely-says-roth-capital/
$SRPT Sarepta: We Believe That Eteplirsen Accelerated Approval Is Likely, Says Roth Capital http://www.smarteranalyst.com/2014/07/23/sarepta-we-believe-that-eteplirsen-accelerated-approval-is-likely-says-roth-capital/
$SRPT Sarepta: We Believe That Eteplirsen Accelerated Approval Is Likely, Says Roth Capital http://www.smarteranalyst.com/2014/07/23/sarepta-we-believe-that-eteplirsen-accelerated-approval-is-likely-says-roth-capital/
$INO VGX-3100 Represents A Completely New Treatment Paradigm For Cervical Cancer, Says Maxim http://www.smarteranalyst.com/2014/07/23/inovio-vgx-3100-represents-a-completely-new-treatment-paradigm-for-cervical-cancer-says-maxim/
$INO VGX-3100 Represents A Completely New Treatment Paradigm For Cervical Cancer, Says Maxim http://www.smarteranalyst.com/2014/07/23/inovio-vgx-3100-represents-a-completely-new-treatment-paradigm-for-cervical-cancer-says-maxim/
$INO VGX-3100 Represents A Completely New Treatment Paradigm For Cervical Cancer, Says Maxim http://www.smarteranalyst.com/2014/07/23/inovio-vgx-3100-represents-a-completely-new-treatment-paradigm-for-cervical-cancer-says-maxim/
$INO VGX-3100 Represents A Completely New Treatment Paradigm For Cervical Cancer, Says Maxim http://www.smarteranalyst.com/2014/07/23/inovio-vgx-3100-represents-a-completely-new-treatment-paradigm-for-cervical-cancer-says-maxim/
$LGND LGND Share Weakness Is Unwarranted, Says Roth Capital; Reiterates Buy
http://www.smarteranalyst.com/2014/07/23/lgnd-share-weakness-is-unwarranted-says-roth-capital-reiterates-buy/
$EXAS Roth Capital Reiterates Buy On Exact Sciences Ahead Of Upcoming Catalysts And Commercial Launch
http://www.smarteranalyst.com/2014/07/23/roth-capital-reiterates-buy-on-exact-sciences-ahead-of-upcoming-catalysts-and-commercial-launch/
$EXAS Roth Capital Reiterates Buy On Exact Sciences Ahead Of Upcoming Catalysts And Commercial Launch
http://www.smarteranalyst.com/2014/07/23/roth-capital-reiterates-buy-on-exact-sciences-ahead-of-upcoming-catalysts-and-commercial-launch/
$EXAS Roth Capital Reiterates Buy On Exact Sciences Ahead Of Upcoming Catalysts And Commercial Launch
http://www.smarteranalyst.com/2014/07/23/roth-capital-reiterates-buy-on-exact-sciences-ahead-of-upcoming-catalysts-and-commercial-launch/
$FB Share Price Reaction Is likely To Be Muted Following 2Q14 Results, Says Topeka http://www.smarteranalyst.com/2014/07/23/share-price-reaction-is-likely-to-be-muted-following-2q14-results-says-topeka/